Latest Video

Markets bulls to dominate: Pro     Tue, 22 Apr '14 | 6:23 PM ET

Ben Lichtenstein, President at Tradersaudio.com, explains why he thinks U.S. stock markets will continue to seek value to the upside.

Leadership in today's market: Cramer     Tue, 22 Apr '14 | 6:00 PM ET

Mad Money host Jim Cramer breaks down the momentum many sectors saw in today's rally.

The Fast Money traders share their final trades of the day.

Xbox battles for your living room     Tue, 22 Apr '14 | 5:48 PM ET

Discussing Xbox series "Every Street United" and pricing competition for original content, with Jonathan Weinbach, Mandalay Sports Media executive producer and senior vice president.

The Fast Money traders take a look at today's biggest market movers.

Options Action: Good deal for Groupon     Tue, 22 Apr '14 | 5:45 PM ET

A bullish bet on Groupon, with CNBC contributor Mike Khouw of Dash Financial Group.

Biogen Idec has room to run: Pro     Tue, 22 Apr '14 | 5:40 PM ET

Mark Newton, Greywolf Execution Partners, looks at biotech's rebound and stabilization in the space.

CNBC's David Faber reports the latest on Valeant and Pershing Square's efforts to acquire Allergan.

Bove: Citi poorly managed     Tue, 22 Apr '14 | 5:18 PM ET

Discussing the fundamental concern of management for Citigroup, with Richard Bove, Rafferty Capital.

Yum Brands beats on bottom line     Tue, 22 Apr '14 | 5:15 PM ET

Yum Brands is reporting Q1 EPS of $0.87 ex-items on revenues of $2.72 billion, with CNBC's Sara Eisen.

Short Netflix: Trader     Tue, 22 Apr '14 | 5:06 PM ET

Dan Nathan of Risk Reversal shorts Netflix's momentum. FM trader Guy Adami weighs in on the trade.

Positive earnings strengthen market     Tue, 22 Apr '14 | 5:00 PM ET

The S&P had its longest winning streak of the year following positive earnings reports from Netflix and Allergan. The Nasdaq erased almost all of its losses since it traded near correction territory on April 11th.

Why buy FireEye     Tue, 22 Apr '14 | 5:00 PM ET

The "Fast Money" traders dissect Brian Kelly's trade on FireEye.

Former Minnesota Governor Jesse Ventura makes the case that CEO pay is "way out of line" and that we should stop cheapening the idea of physical labor. "Shark Tank" investor Kevin O'Leary and CNBC's Kate Kelly weigh in.

A recent report shows that over 1,000 IRS employees with "federal tax compliance problems" received more than $1 million in bonuses. CNBC's Eamon Javers reports.

Matt Levatich, Harley-Davidson president and COO, discusses international opportunities and looks at its distribution channel as a strength for the motorcycle maker.

Merger mania sweeps Wall Street     Tue, 22 Apr '14 | 5:00 PM ET

CNBC's Patti Domm discusses the amount of merger activity happening this week with a big three-way deal in the drug industry, and the $46 billion bid by Valeant and activist Bill Ackman for Allergan.

Terry Duffy, CME Group executive chairman, doesn't believe the market is "rigged" and looks at the wealth and opportunities it creates for investors and companies. Michael Gayed, The Inflation Rotation Fund, and CNBC's Sharon Epperson weigh in on the high-frequency trading controversy.

Ackman front-running Valeant's bid?     Tue, 22 Apr '14 | 4:12 PM ET

Providing insight on Bill Ackman and Valeant's proposed takeover of Allergan, with former SEC chairman Harvey Pitt and CNBC's Kate Kelly.

CNBC's Jackie DeAngelis discusses the day's activity in the commodities markets. Crude oil prices were under pressure; traders are eying tomorrow's Department of Energy report; natural gas got a small bump up, closing at $4.74, and traders are looking for a catalyst to get back on the long side of gold.

Show me accretive pharma: O'Leary     Tue, 22 Apr '14 | 4:06 PM ET

"Shark Tank" investor Kevin O'Leary discusses recent mergers between pharmaceutical companies.

Gilead earnings blowout: Pro     Tue, 22 Apr '14 | 4:09 PM ET

Providing instant analysis to Gilead and Amgen's quarterly numbers, with David Nelson, Belpointe Asset Management, and CNBC's Sharon Epperson and Kate Kelly.

Big Q1 for Gilead     Tue, 22 Apr '14 | 4:07 PM ET

Gilead is reporting Q1 EPS of $1.48 adj. on revenues of $5.00 billion, with CNBC's Meg Tirrell.

Amgen Q1 earnings miss     Tue, 22 Apr '14 | 4:06 PM ET

Amgen is reporting Q1 EPS of $1.87 ex-items on revenues of $4.52 billion, with CNBC's Meg Tirrell.

AT&T beats on earnings     Tue, 22 Apr '14 | 4:05 PM ET

AT&T is reporting Q1 EPS of $0.71 on revenue of $32.5 billion, with CNBC's Dominic Chu.

Stephen Wood, Russell Investments chief market strategist, and Terry Dolan, Benjamin & Jerold Brokerage CEO, discuss if the market is approaching a double top.

No rhyme or reason to rally: CEO     Tue, 22 Apr '14 | 3:49 PM ET

Discussing their investment strategies in this market rally, with Stephen Wood, Russell Investments chief market strategist, and Terry Dolan Benjamin & Jerold Brokerage CEO.

Biotech earnings: All eyes on Gilead     Tue, 22 Apr '14 | 3:45 PM ET

CNBC's Meg Tirrell previews the earnings of biotech players Gilead and Amgen. Tirrell explains why investors will be focusing on Gilead's Sovaldi sales.

Eco-investing for 'green' returns     Tue, 22 Apr '14 | 3:39 PM ET

Leslie Samuelrich, Green Century Capital Management president, explains how investors can capitalize in ways that are "green" and "friendly" to the environment and shares her best eco-friendly buys.

Jeffery Harte, Sandler O'Neill principal, weighs in on the recent turmoil at Citigroup, including fraud at its Mexican operations. CNBC's Kayla Tausche provides insight.

Contact Latest Video


    Get the best of CNBC in your inbox

    › Learn More

Video and TV

Tuesday, 22 Apr 2014 | 1:19 PM ET

Porter Bibb, MediaTech Capital Partners, shares his thoughts on the likely outcome of the Aereo case and who will be the winners and losers.

Tuesday, 22 Apr 2014 | 1:10 PM ET

Barbara Ryan, CNBC contributor, shares an inside look at what's happening among the drug giants as billion dollar deals are announced and big player reshape the industry.

Tuesday, 22 Apr 2014 | 12:33 PM ET

The Futures Now team discusses what's likely driving the increase in gasoline prices.

U.S. Video

  • CNBC's David Faber and Carl Icahn, chairman, Icahn Enterprises, discuss corporate boards, a dysfunctional system, his impact as an activist investor and why what he does is important, as well as the use of poison pills to fend off activists. He also finds himself in the unusual position of defending Bill Ackman's recent efforts to partner with Valeant and acquire Allergan.

  • Discussing new technology in the Permian, growing market in North America, and higher earnings, with Dave Lesar, Halliburton chairman, president and CEO.

  • Paul Raines, GameStop CEO, discusses how its leadership in digital sales, market share, and ability to drive loyalty with rewards propels consumers to stay with the gaming store.

Asia Video

Europe Video

Most Popular Video

Tuesday, 22 Apr 2014 | 10:48 PM ET

Todd Elmer, Currency Strategist at Citi, discusses whether the currency's sharp drop following weaker-than-expected quarterly inflation data was justified.

Tuesday, 22 Apr 2014 | 10:30 PM ET

Adaire Fox-Martin, COO, Asia Pacific Japan at SAP, elaborates on the firm's "stunning results" in Southeast Asia, India and the sector of cloud computing in the first-quarter.

Tuesday, 22 Apr 2014 | 10:17 PM ET

Joe Magyer, Senior Analyst at The Motley Fool, says the flurry of activity on Wall Street looks "frothy" at the moment.